Papers/PMID:34150674
Effects of Oral Liposomal Glutathione in Altering the Immune Responses Against Mycobacterium tuberculosis and the Mycobacterium bovis BCG Strain in Individuals With Type 2 Diabetes.
Frontiers in cellular and infection microbiology2021The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
glutathione — decreases intracellular BCG burden in PBMC-derived granulomas (CFU)
Evidence strength: moderate.Finding“When compared to the placebo group, PBMCs isolated from individuals with T2DM who received L-GSH supplementation for 3-months had a significantly reduced burden of BCG.”
Quoted verbatim from Effects of Oral Liposomal Glutathione in Altering the Immune Responses Against Mycobacterium tuberculosis and the Mycobacterium bovis BCG Strain in Individuals With Type 2 Diabetes.. - Study
- RCT
- Duration
- 3 months
- Dose
- oral liposomal reduced glutathione, 1260 mg/day (3 teaspoons, 15 ml, in two divided doses)
- Population
- Adults aged 18-65 with type 2 diabetes (HbA1c 7-13%); PBMCs drawn at 3 months, infected with M. bovis BCG in vitro, granulomas terminated at 15 days
Effects of Oral Liposomal Glutathione in Altering the Immune Responses Against Mycobacterium tuberculosis and the Mycobacterium bovis BCG Strain in Individuals With Type 2 Diabetes.2021PMID:3415067410.3389/fcimb.2021.657775Permalink